secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001764013-24-000150
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant stockholders elect directors, ratify auditor, approve compensation at 2024 annual meeting
--------------------------------------------------------------------------------

- Three directors (Salzmann, Migausky, Hughes) elected with over 97M votes for each, ~6.5M broker non-votes.
- Ernst & Young ratified as auditor for FY ending March 31, 2025: 138,241,628 for, 16,740 against.
- Non-binding advisory approval of named executive officer compensation: 128,494,310 for, 3,249,170 against.
- Approximately 95% of eligible shares (138.3M) represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401324000150/0001764013-24-000150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401324000150/imvt-20240812.htm
  HTML page:      https://secwatch.observer/filing/0001764013-24-000150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer